Online inquiry

IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7023MR)

This product GTTS-WQ7023MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) Cancers (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, Fab C225(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7023MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8553MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ11805MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-3475
GTTS-WQ14693MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ15683MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ6806MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ1941MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ9154MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ1531MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-031
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW